Ferring Pharmaceuticals clinical trial pipeline

3 trials changed in the last 30 days: 0 stopped, 0 with notable changes, 3 with minor changes only.

1. Minor

   LYCHEE · REKOVELLE in Chinese Women Undergoing Assisted…LYCHEE · REKOVELLE in Chinese Women Undergoing Assisted Reproductive Technologies: Effectiveness, Safety, and Patterns of Use in Real-world Practice

   Enrollment closed, study ongoing

   Ferring Pharmaceuticals·Not specified· NCT07029451· Registry history of NCT07029451 on ClinicalTrials.gov (opens the registry)

   Sep 25, 2026

2. Minor

   ABLE-32 · Nadofaragene Firadenovec vs. Observation · Intermediate…ABLE-32 · Nadofaragene Firadenovec vs. Observation · Intermediate Risk Non-Muscle Invasive Bladder Cancer

   Trial sites expanded: 111 → 114 locations

   And 1 more change in the last 30 days

   Ferring Pharmaceuticals·Phase 3· NCT06510374· Registry history of NCT06510374 on ClinicalTrials.gov (opens the registry)

   Oct 16, 2026

3. Minor

   ABLE-22 · Intravesical Nadofaragene Firadenovec Alone or in…ABLE-22 · Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy · High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer

   Trial sites expanded: 76 → 80 locations

   Ferring Pharmaceuticals·Phase 3· NCT06545955· Registry history of NCT06545955 on ClinicalTrials.gov (opens the registry)

   Sep 25, 2026

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.